David Chiswell

Kymab

• 
• 
• 
• 
• 
• http://www.kymab.com/

Overview

Dr Chiswell co-founded Cambridge Antibody Technology (CAT) in 1990 and was responsible for operational management, serving as CEO from 1996 to 2002. CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001 raising over £120m on the public markets. Since leaving CAT in 2002 he has focused on the development of early stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics and Daniolabs, and as CEO of Nabriva Therapeutics (2009 to 2012). Dr Chiswell currently serves as chairman of Nabriva Therapeutics and Albireo Pharma. He is a past chairman of the UK BioIndustry association (BIA) and in 2006 he was awarded the OBE by HM The Queen for services to the biotechnology industry.